Showing posts with label biomarker. Show all posts
Showing posts with label biomarker. Show all posts

Thursday, September 23, 2010

Strategy to build a complete catalogue of human proteins could put China in a leading position

First the genome; now the proteome. China has already established a leading position in DNA sequencing through the work of the BGI in Shenzhen (formerly the Beijing Genomics Institute), which has been generating eye-catching genomics discoveries for the past few years (see Nature 464, 22–24; 2010). This week, Chinese researchers are set to announce initiatives that could put them at the forefront of international efforts to catalogue and characterize all proteins in the human body. Inspired by the Human Genome Project, protein researchers worldwide have been seeking funds to build a full catalogue of human proteins — a proteome — which, they say, will explain how the information encoded in our genomes can give rise to normal and diseased states.

his January, the Human Proteome Organization (HUPO) in Montreal, Canada, took the first steps towards an international effort. It set up the Human Proteome Project (HPP) working group to coordinate researchers who are characterizing the products of the 21,000 or so protein-coding genes in the human genome (see Nature 452, 920–921; 2008). But funding agencies worldwide have yet to show full support for the scheme, which is likely to carry a multi billion-dollar price tag. There is also uncertainty over the scope of the project — each human protein can be modified in an as-yet-unspecified number of ways — and over how well data from different labs can be compared (A. W. Bell et al. Nature Methods 6, 423–430; 2009).

However, this week, Chinese researchers travelled to HUPO's annual congress in Sydney, Australia, to announce plans that defy such scepticism. The Beijing Proteome Research Center, directed by biochemist He Fuchu, has received average grants of roughly 200 million renminbi (US$30 million) per year as one of several institutes involved in HUPO's Human Liver Proteome Project (seeNature 425, 441; 2003). That budget, He says, is soon set to double as the initiative — now renamed the Chinese Human Proteome Project — expands to cover proteins in the blood, brain, lungs, skin and other organs. The Chinese government also plans to invest 1.2 billion renminbi in a national laboratory called the Pilot Hub of Encyclopedical proteomIX (PHOENIX), which has been several years in the planning.

"The investment is impressive and unprecedented," says Ruedi Aebersold, a proteomics expert at the Swiss Federal Institute of Technology in Zurich and a member of the HPP working group. "The launch of a large project in China would give the whole HPP project a significant boost. "The PHOENIX project will include a doubling of facilities for nuclear magnetic resonance imaging at Peking University, already the largest facility for structure determination in China but heavily oversubscribed. Tsinghua University's electron microscope facility will be expanded, and there will be more capacity for protein-structure studies at the Institute of Biophysics of the Chinese Academy of Sciences in Beijing.

But the core of the project, and half the budget, will go to He's new mass spectroscopy centre, to be built near the Beijing Proteome Research Center. The cash will buy 20 new mass spectrometers, bringing the total number in the centre to 29. They will be integrated with a robotic pipeline for high-throughput processing of proteins, including bioinformatic analysis. It will be the "first laboratory in the world to reach that level of integration", says He.
China's human proteome project will build on the success of He's liver project, which he says produced the largest human organ proteome to date, encompassing nearly 7,000 proteins (A. Sun et al. J. Proteome Res. 9, 50–58; 2010). At the Sydney meeting, He plans to discuss unpublished work that maps protein–protein interactions and their localization. "It's a real, comprehensive demonstration for other organs," he says.

Wednesday, September 15, 2010

Agorithm from Blood-Based Alzheimer's Biomarkers


In a study appearing in the newest issue of the Archives of Neurology, members of the Texas Alzheimer's Research Consortium reported that they have identified protein biomarkers in the blood that can be used to distinguish between individuals with and without Alzheimer's disease.
The researchers compared protein patterns in blood samples from hundreds of individuals with or without Alzheimer's disease and incorporated these potential biomarkers into an algorithm for detecting Alzheimer's cases in a test group. Their results so far suggest this algorithm can accurately classify most Alzheimer's cases — particularly when combined with APOE status and demographic data.
And, they said, information from the biomarker study is offering clues about possible sub-groups within Alzheimer's. For instance, by looking at some of the proteins that are frequently expressed at different levels in the blood of those with Alzheimer's disease, the team identified a potential subset of individuals with inflammation-related biomarker patterns.

Share |

Thursday, August 6, 2009

BioFocus, Oncodesign Strike Partnership

BioFocus DPI has partnered with the cancer drug candidate and biomarker company Oncodesign to offer an integrated service platform, Galapagos division BioFocus DPI said today.

The agreement will create a service that combines BioFocus DPI's target discovery and screening capabilities with Oncodesign's biomarker and pharmacological services to offer target validation and clinical candidate selection services, the company said.

BioFocus DPI offers gene-to-drug candidate discovery services, including in vitro and cell-based screening, chemogenomic and informatics offerings, storage, distribution, and other structural biology and medicinal chemistry services.


XTractor Premium - A Platform for discovery, knowledge sharing, analysis and modelling of published biomedical facts.









Thursday, June 4, 2009

Grants galore, US is recession profing by encoraging companies in biotechnology industry

Integrated Genomics gets $250K from Wisconsin State

Wisconsin will provide $250,000 to Integrated Genomics through a combination of a loan and a grant, and the company plans to relocate its laboratory and commercial operations from Chicago to Madison, the state's governor's office said Tuesday. The state will give the microbial genomics and gene expression services and technologies company a loan of $200,000 and a grant of $50,000 from the Technology Venture Fund. It said that Integrated Genomics' move could create up to 18 new jobs.

Compugen Gets $500K in Grants from Israel

The company plans to use the funding to pay for relocating the laboratory to Madison and to buy equipment. Wisconsin Governor Jim Doyle said in a statement that Integrated Genomics "is exactly the type of company our state should be investing in – companies that are developing innovative solutions in the biotechnology industry."

Compugen said today that it will receive grants totaling around $500,000 from the Office of the Chief Scientist of Israel to fund the firm's drug and diagnostic product candidate discovery activities. Tel Aviv, Israel-based Compugen said that it would use the grant money to discover additional drug targets for antibody therapeutics and preclinical nucleic acid biomarkers for drug-induced toxicity. The firm said these activities would be based on "modifying and enhancing" its 10 existing discovery platforms.

Compugen also said that it would use a portion of the funds to develop additional computational methods predicting genes, mRNA transcripts, proteins, and peptides that appear most suitable for development as therapeutic and diagnostic products.



XTractor Premium - A Platform for discovery, analysis and modelling of published biomedical facts.









Tuesday, July 29, 2008

Blood Biomarkers for the Presence of Ruptured Atherosclerotic Plaques Identified

A research team from the University of Maastricht, The Netherlands, found biomarkers to detect the presence of ruptured atherosclerotic plaques. They observed that the blood of individuals with ruptured atherosclerotic plaques contained antibodies reactive against two peptides, E1 and E12.

The presence of these antibodies was detected extremely early after the onset of symptoms of a heart attack, according to the investigators. They caution, though, that further studies on additional patients are needed before this work can be translated into the clinic.




Be a part of the XTractor community. XTractor is the first of its kind - Literature alert service, that provides manually curated and annotated sentences for the Keywords of user preference. XTractor maps the extracted entities (genes, processes, drugs, diseases etc) to multiple ontologies and enables customized report generation. With XTractor the sentences are categorized into biological significant relationships and it also provides the user with the ability to create his own database for a set of Key terms. Also the user could change the Keywords of preference from time to time, with changing research needs. The categorized sentences could then be tagged and shared across multiple users. Thus XTractor proves to be a platform for getting real-time highly accurate data along with the ability to Share and collaborate.

Sign up it's free, and takes less than a minute. Just click here:www.xtractor.in.











Sunday, July 27, 2008

Molecular Connections perceives inorganic growth path

Molecular Connections, a life sciences informatics major, is now looking at acquiring small and medium-sized companies as part of its inorganic growth strategy.

"The acquisition will depend on good technology fit and domain expertise that could plug into our products and services,'' Jignesh Bhate, CEO, Molecular Connections Pvt Ltd told Pharmabiz.

"We are aggressively scouting for companies both in India and abroad. If we lay our hands on an international company, we will have access to their customers. In the case of an Indian company, we are essentially looking at a synergy in content and database,'' Bhate said.

To facilitate these acquisitions, Molecular Connections has identified three options to raise funds: internal accruals, foreign loans and venture funds. The mode of raising capital will depend on the size of the deal and the company is in talks with foreign banks. Around $2 million was raised from Barings Private Equity in 2006 for expansion.

Early this month, Molecular Connections was adjudged as the most promising company of the year by CNBC-ICICI for the Emerging India Awards out of more than 3.5 lakh entries.

The company, with sound financials, was also recognized as one of the fastest growing companies in the Technology Fast 50 India 2007 survey conducted by Deloitte Touche Tohmatsu, Asia Pacific. Molecular Connections was ranked 8th in India in the overall category.

The six-year-old company's product portfolio of informatics solutions focuses on protein interaction mechanisms of biological processes and also Biomarkers. Its maiden offering NetPro, the largest database globally on protein-protein has been upgraded with pharmacokinetics model. This is a market leader with repeat subscriptions from GSK, Aventis, Merck, Becton & Dickenson's bio-pharma unit and Galapagos NV, a drug discovery company.

The second product, CliPro's new version has been supplemented with biomarker data for clinical data. A recent product, Receptome is a comprehensive database of Functional Ligand-Receptor Complexes. Another new product, 'Xtractor' is a literature alert service, giving manually curated sentences of keywords as given by scientists.

All products are targeted at international customers because investments in informatics are increasing globally and the sector is getting its due importance. India pharma-biotech space will take a few years to utilize informatics' solutions offered from Molecular Connections, stated Bhate.

With collaborations helping to open a new dimension in research, Molecular Connections has partnered with the Bangalore-based Connexious Life Sciences for pathway work. Recently, it has teamed up with the Indian Institute of Science for a department of Biotechnology grant. The company's CYP database will be utilized by Prof P Kondaiah from the Department of Molecular Reproduction, Development & Genetics to customize drugs for the Indian population.

The global informatics market is valued at $6-8 billion. Of these four areas comprising validation & target identification, clinical development including toxicity studies, lead optimization studies, part of combinatorial chemistry is estimated at $6-8billion. Right now, Molecular Connections has the expertise in validation & target identification and is honing its skills in the area of ADME/TOX side and combinatorial chemistry.

Be a part of the XTractor community. XTractor is the first of its kind - Literature alert service, that provides manually curated and annotated sentences for the Keywords of user preference. XTractor maps the extracted entities (genes, processes, drugs, diseases etc) to multiple ontologies and enables customized report generation. With XTractor the sentences are categorized into biological significant relationships and it also provides the user with the ability to create his own database for a set of Key terms. Also the user could change the Keywords of preference from time to time, with changing research needs. The categorized sentences could then be tagged and shared across multiple users. Thus XTractor proves to be a platform for getting real-time highly accurate data along with the ability to Share and collaborate.

Sign up it's free, and takes less than a minute. Just click here:www.xtractor.in.










Friday, May 16, 2008

Biomarkers Predict Heart Deaths

Blogging previously about biomarker in, Biomarkers to Open the Door to Personalized Medicine and Represents a Seismic Shift for the Pharma Industry. Here are two interesting study on biomarkers. First one, Dr. Johan Arnlov, a researcher at Uppsala University, and lead author of a report in the May 15 issue of the New England Journal of Medicine. A bundle of four offbeat biomarkers accurately predicted the risk of death from cardiovascular disease in a study of older Swedish men, researchers report. It is just a preliminary finding in a long process that might one day lead to widespread medical use of these biomarkers in addition to well-established risk factors such as high blood pressure and cholesterol.

And second one, Potential cardiovascular disease markers – CliPro™ based analysis:

Introduction

Quantitative analysis of proteins in body fluids for disease diagnosis has attained significant clinical relevance as it could reflect the pathophysiological state of the organism. Despite the wide concentration ranges and limitations of certain analytical techniques, the utility of the plasma proteome as a principle diagnostic material for biomarker analysis is on the rise (Anderson et al., 2002; Anderson et al., 2004; Adkins et al., 2002). Cardiovascular disease (CVD) is one of the leading causes of death, though preventable. Understanding of pathophysiological components and their role in diagnosis and timely prediction could become vital in this largely preventable disease. Analyzing the plasma proteome using CliPro™ has helped us to identify and validate potential biomarker-CVD disease association.

Using literature-mining efforts, we have systematically compiled a list of plasma proteins that contains concentration values reflecting alterations between normal versus various disease states. Using CliPro™, we found significant differences in the levels of some of the plasma proteins, influenced by genetics, sex, age, physiological state and various factors. Of the many protein candidates, we have prioritized a list of around 180 clinically significant plasma proteins of different types with their concentration ranges reflecting a clear-cut CVD association. By analyzing the concentration values of the plasma proteins in disease versus normal conditions, we find that more than 50% of the proteins clearly serve as biomarkers, which will enable to measure the presence/ progress of a disease or the effect of therapeutic intervention in the treatment of a disease.

Do you want to know more?


Tuesday, May 6, 2008

Biomarkers to Open the Door to Personalized Medicine and Represents a Seismic Shift for the Pharma Industry

“For example, the presence of a specific protein in the blood or in any body fluid might indicate a specific infection. Once an association between a biomarker and a disease is clearly established, the one can be used to signal the other, and to a high degree of certainty. As well, changes in the prevalence of a biomarker in the organism can immediately and reliably signpost a patient’s response to treatment”

Some pharmaceutical companies are already advancing their research and harnessing the power of biomarkers, which can:
  • Be used to detect the predisposition for disease in a population, screen for its presence, confirm its diagnosis, assess its severity, predict its response to available therapies and measure its clinical course
  • Be used as targets to discover new drugs
  • Be a decisive factor in determining whether or not to continue research on an entity
  • Show early in the development phase whether an entity could lead to side effects that should terminate further research
  • Help to make clinical trials more efficient
  • Reduce treatment overheads by optimizing dosages and measuring a patient’s response more quickly and accurately
Molecular Connections Private Ltd. Bangalore India has announced the launch of its new Knowledgebase of Clinically Significant Proteins - CliPro.
  • Knowledgebase, is a result of manually mining thousands of papers, on proteins present in various human body fluids , with their known concentration values and biomarker information as available in literature
  • Platform to analyze protein biomarker- disease associations
  • Catalogue of clinically significant proteins in biofluids such as plasma, cerum, CSF, synovial fluid, saliva, urine, peritonial fluid, bal fluid, amniotic fluid, tears
  • includes >1000 clinically significant proteins – with ~2000 different disease/pathological correlations
  • Biomarkers with disease associations are broadly either diagnostic, prognostic, predictive or efficacy markers
Also read A price tag of around US$1 billion to map human proteome